Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Interstitial Lung DiseaseCommon Variable Immunodeficiency
Interventions
DRUG

Abatacept

Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.

OTHER

Placebo

The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.

Trial Locations (6)

27710

RECRUITING

Duke University Health System, Durham

33620

RECRUITING

University of South Florida, Tampa

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

55902

RECRUITING

Mayo Clinic, Rochester

94143

RECRUITING

University of California, San Francisco, San Francisco

01805

RECRUITING

Lahey Hospital and Medical Center, Burlington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT04925375 - Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease | Biotech Hunter | Biotech Hunter